Yes, hyperbaric oxygen therapy can help some people with long COVID, but the benefit is modest, partly placebo-driven, and far short of a cure. The strongest randomized trial, published in 2023, found that 100% oxygen at 2.0 atmospheres improved quality of life and reduced fatigue in long COVID patients, yet roughly a third of the improvement seen across symptoms also appeared in sham-treated controls. Hyperbaric oxygen is best viewed as one investigational option in a rehabilitation plan, not a proven standalone treatment.
How Hyperbaric Oxygen Might Work in Long COVID
Hyperbaric oxygen therapy, or HBOT, means breathing 100% oxygen inside a pressurized chamber. Treatment pressures typically run 1.5 to 2.5 atmospheres absolute (ATA), compared with the 1.0 ATA of normal sea-level air. At 2.0 ATA, the oxygen dissolved directly in blood plasma can rise to roughly 1.5 to 2.0 milliliters per deciliter, dozens of times normal. That dissolved oxygen reaches tissue without waiting for red blood cells.
The long COVID hypothesis rests on four mechanisms. First, hyperoxia raises tissue oxygen tension in poorly perfused organs, including brain and muscle. Second, it appears to calm chronic neuroinflammation by shifting microglia and cytokine signaling. Third, oxygen exposure may improve mitochondrial function in cells left energetically impaired after infection. Fourth, pressure and oxygen together may help mobilize circulating stem cells and reduce microclots.
In plain terms: the theory holds that long COVID leaves some tissues starved of oxygen and inflamed, and HBOT floods those tissues with oxygen while damping inflammation. That is plausible biology, not proven causation. No trial has yet shown that symptom relief tracks directly with measured oxygen delivery to the brain.
The Trial Numbers That Matter
The key randomized evidence comes from a 2023 double-blind, sham-controlled trial by Zilberman-Itskovich and colleagues in Scientific Reports. It enrolled 73 long COVID patients who had persistent symptoms at least three months after infection. Participants received 40 sessions of either HBOT at 2.0 ATA or sham air at 1.03 ATA. Each session lasted about 90 minutes, five days a week for eight weeks.
| Outcome measure | HBOT group | Sham group | Interpretation |
|---|---|---|---|
| Quality of life (EuroQol score) | Improved significantly | No significant change | Largest HBOT advantage |
| Fatigue (Chalder scale) | Meaningful improvement | Some improvement | Partial sham response |
| Cognitive symptoms | Improved | Smaller improvement | Consistent but modest |
| Sleep quality | Improved | Minimal change | Secondary benefit |
| Symptom reduction overall | Roughly 1 in 3 did not respond | Most stayed stable | Edge case: non-responders |
The headline is real but qualified. The HBOT arm improved on quality of life, fatigue, cognition, and sleep, and brain imaging showed changes in white-matter microstructure. However, the sample was small at 73 patients, and many outcomes relied on self-report, which inflates placebo effects. A 2024 systematic review pooled early HBOT long COVID data and concluded the evidence was promising but low to moderate certainty because of small cohorts and inconsistent protocols. In plain terms: patients often feel better, and the signal is stronger than pure noise, but no single trial is large enough to make HBOT standard care.
HBOT vs. Other Long COVID Approaches
Long COVID has no approved drug, so every option competes on evidence quality and cost. The table below compares HBOT with the most-discussed alternatives on the dimensions that matter to patients.
| Approach | Typical protocol | Evidence quality for long COVID | Out-of-pocket cost (US) | Key caveat |
|---|---|---|---|---|
| Hyperbaric oxygen | 40 sessions at 1.5-2.5 ATA | One small RCT plus reviews; low to moderate certainty | USD 200-400 per session; USD 8,000-16,000 total | Uninsured in most US plans |
| Graded exercise / rehab | Supervised, 6-12 weeks | Moderate; benefit in fatigue and function | Low, often covered | Post-exertional crash risk in some |
| Antihistamine regimens | Off-label, weeks to months | Anecdotal; mechanistic rationale only | Low, USD 10-50 monthly | No RCT support |
| Low-dose naltrexone | 1.5-4.5 mg nightly | Small trials; mixed results | Low, USD 30-60 monthly | Off-label |
| Pacing and energy management | Ongoing behavioral | Moderate for symptom control | Minimal | Does not reverse mechanism |
The comparison is sobering. HBOT is the most expensive option on the list and among the weakest in trial size. Rehab and pacing carry equal or better evidence at a fraction of the cost. Antihistamines and low-dose naltrexone have thinner evidence than HBOT but cost 100 to 500 times less per month. In plain terms: HBOT is a high-cost, medium-confidence bet, and cheaper strategies deserve a trial first.
What the Timeline Looks Like
Patients ask how fast HBOT works and how long relief lasts. Protocols cluster around 30 to 40 sessions over 6 to 10 weeks, with effects assessed at the end of the course. Durability data remain thin; most trials stopped measuring at three months.
| Time point | What typically happens |
|---|---|
| Sessions 1-10 | Little measurable change; some report sleep shift |
| Sessions 11-20 | Early fatigue and cognitive improvements in responders |
| Sessions 21-40 | Peak quality-of-life gains reported in trials |
| End of course (week 8-10) | Outcomes measured; non-responders identified |
| 1-3 months after | Gains largely maintained in reported cohorts |
| Beyond 3 months | Little published durability data |
| Repeat course | Sometimes offered; no trial evidence for retreatment |
The absence of long-term data is a real limitation. A patient spending USD 12,000 on a 40-session course deserves to know that evidence of benefit beyond three months is essentially unpublished. Trial follow-up of six months or more is needed before durability claims can be made.
Misconceptions and Professional Caveats
Several beliefs about HBOT and long COVID are wrong or overstated. Correcting them matters before anyone spends five figures.
The first misconception is that HBOT removes spike protein or "clears" the virus. There is no evidence HBOT eliminates viral reservoirs. Any benefit likely comes from oxygen delivery and anti-inflammatory effects, not antiviral action.
The second is that more pressure is better. Trials used 2.0 ATA, and pressures above 2.5 ATA raise risks of barotrauma and oxygen toxicity without proven extra benefit in long COVID. Dose-response in this condition is unestablished.
The third is that the sham-controlled results prove HBOT works. They show a real but partial signal, and the placebo response was substantial. A third of participants in some analyses did not respond at all, and predictors of response remain unknown. In plain terms: HBOT helps some patients meaningfully and leaves others unchanged, and nobody can yet predict which group you fall into.
A fourth caveat is commercial. Many clinics market HBOT for long COVID with testimonials rather than trial citations, and insurance coverage in the US is rare. Per the Undersea and Hyperbaric Medical Society, long COVID is not among the 14 accepted indications for HBOT, which means most insurers will decline coverage.
Safety and Red Flags
HBOT at 2.0 ATA is generally safe in supervised settings, but risks are real and should be weighed against modest benefit. Stop and seek medical evaluation if any of the following occur:
- Ear pain, muffled hearing, or eardrum rupture from pressure changes.
- Chest tightness, cough, or shortness of breath suggesting pulmonary oxygen toxicity.
- Visual changes such as temporary nearsightedness, which is common and usually reversible.
- Seizure, which is rare at 2.0 ATA but more likely at higher pressures.
- Claustrophobia or panic during pressurization.
- Worsening fatigue after sessions, which may signal post-exertional overload.
Absolute contraindications include untreated pneumothorax. Relative cautions include certain lung conditions, implanted devices not cleared for pressure, and pregnancy outside approved indications. Sessions should be run by credentialed hyperbaric physicians, not in unregulated wellness chambers.
What to Actually Do
If you are considering HBOT for long COVID, a structured approach protects both your health and your wallet.
- Confirm the diagnosis and rule out other causes of fatigue and breathlessness with your primary care clinician first.
- Ask whether the clinic follows a published trial protocol, ideally 40 sessions at 2.0 ATA over eight weeks.
- Request the clinic's outcome data and complication rates, not testimonials.
- Set a defined stopping point, such as 20 sessions, and reassess fatigue and cognition objectively.
- Trial cheaper evidence-based options such as supervised rehab and pacing before committing USD 8,000 or more.
- Check insurance coverage in writing, since long COVID is not an accepted HBOT indication for most US plans.
The honest bottom line is that HBOT for long COVID is a genuine but limited lead. It has one small randomized trial showing meaningful quality-of-life gains, a plausible anti-inflammatory and oxygen-delivery mechanism, and a cost that dwarfs cheaper alternatives with equal or better evidence. It belongs in research settings and carefully monitored individual trials, not in routine care. Patients who pursue it should do so with clear expectations, defined endpoints, and a clinician who will stop the course if the numbers do not move.